Next Article in Journal
Rectal Cancer: 20% Risk Reduction Thanks to Dietary Fibre Intake. Systematic Review and Meta-Analysis
Next Article in Special Issue
Food-Intake Normalization of Dysregulated Fatty Acids in Women with Anorexia Nervosa
Previous Article in Journal
Consumer Perceptions and Acceptability of Traditional Dishes Prepared with Provitamin A-Biofortified Maize and Sweet Potato
Previous Article in Special Issue
Precision Nutrition and the Microbiome Part II: Potential Opportunities and Pathways to Commercialisation
 
 
Review

The Potential Use of Metabolic Cofactors in Treatment of NAFLD

1
Science for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden
2
Centre for Host–Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London SE1 9RT, UK
3
School of Medicine, Koç University, Istanbul 34450, Turkey
4
Department of Gastroenterology and Hepatology, School of Medicine, Koç University, Istanbul 34450, Turkey
5
Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital Gothenburg, 41345 Gothenburg, Sweden
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1578; https://doi.org/10.3390/nu11071578
Received: 1 May 2019 / Revised: 4 July 2019 / Accepted: 5 July 2019 / Published: 12 July 2019
(This article belongs to the Special Issue Precision Nutrition and Metabolic Disease)
Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction. View Full-Text
Keywords: NAFLD; metabolic cofactors; l-carnitine; nicotinamide riboside; l-serine; N-acetyl-l-cysteine NAFLD; metabolic cofactors; l-carnitine; nicotinamide riboside; l-serine; N-acetyl-l-cysteine
Show Figures

Figure 1

MDPI and ACS Style

Mardinoglu, A.; Ural, D.; Zeybel, M.; Yuksel, H.H.; Uhlén, M.; Borén, J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 2019, 11, 1578. https://doi.org/10.3390/nu11071578

AMA Style

Mardinoglu A, Ural D, Zeybel M, Yuksel HH, Uhlén M, Borén J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients. 2019; 11(7):1578. https://doi.org/10.3390/nu11071578

Chicago/Turabian Style

Mardinoglu, Adil, Dilek Ural, Mujdat Zeybel, Hatice Hilal Yuksel, Mathias Uhlén, and Jan Borén. 2019. "The Potential Use of Metabolic Cofactors in Treatment of NAFLD" Nutrients 11, no. 7: 1578. https://doi.org/10.3390/nu11071578

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop